Xeris Pharmaceuticals Stock Performance
| XERS Stock | USD 4.82 0.26 5.70% |
On a scale of 0 to 100, Xeris Pharmaceuticals holds a performance score of 16. The firm maintains a market beta of 0.51, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Xeris Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Xeris Pharmaceuticals is expected to be smaller as well. Please check Xeris Pharmaceuticals' sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to make a quick decision on whether Xeris Pharmaceuticals' historical returns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Xeris Pharmaceuticals are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Xeris Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 5.7 | Five Day Return 16.99 | Year To Date Return 39.31 | Ten Year Return (76.16) | All Time Return (76.16) |
Last Split Factor 1:1 | Last Split Date 2021-10-06 |
1 | Disposition of 320 shares by Hecht Beth of Xeris Pharmaceuticals at 3.61 subject to Rule 16b-3 | 01/03/2025 |
2 | The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness | 01/21/2025 |
3 | Disposition of 25842 shares by Johnson Kenneth Erland of Xeris Pharmaceuticals at 3.56 subject to Rule 16b-3 | 01/31/2025 |
4 | Acquisition by John Shannon of 800000 shares of Xeris Pharmaceuticals subject to Rule 16b-3 | 02/03/2025 |
5 | Xeris Pharmaceuticals stock hits 52-week high of 3.87 By Investing.com - Investing.com Nigeria | 02/18/2025 |
6 | Disposition of 14037 shares by Hecht Beth of Xeris Pharmaceuticals at 2.11 subject to Rule 16b-3 | 02/21/2025 |
7 | Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer | 02/24/2025 |
8 | Insider Trading | 02/25/2025 |
9 | Aclaris Therapeutics Reports Q4 Loss, Tops Revenue Estimates | 02/27/2025 |
10 | Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results and Announces 2025 Guidance | 03/06/2025 |
11 | Xeris Biopharma Holdings Inc Q4 2024 Earnings Call Highlights Surpassing Revenue ... | 03/07/2025 |
12 | Leerink Partners Issues Positive Forecast for Xeris Biopharma Stock Price | 03/10/2025 |
13 | Xeris Pharmaceuticals stock hits 52-week high at 4.69 - Investing.com | 03/14/2025 |
| Begin Period Cash Flow | 71.7 M |
Xeris |
Xeris Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 337.00 in Xeris Pharmaceuticals on December 15, 2024 and sell it today you would earn a total of 145.00 from holding Xeris Pharmaceuticals or generate 43.03% return on investment over 90 days. Xeris Pharmaceuticals is currently generating 0.6335% in daily expected returns and assumes 3.0526% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Xeris, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Xeris Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xeris Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Xeris Pharmaceuticals, and traders can use it to determine the average amount a Xeris Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2075
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | XERS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.05 actual daily | 27 73% of assets are more volatile |
Expected Return
| 0.63 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.21 actual daily | 16 84% of assets perform better |
Based on monthly moving average Xeris Pharmaceuticals is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Xeris Pharmaceuticals by adding it to a well-diversified portfolio.
Xeris Pharmaceuticals Fundamentals Growth
Xeris Stock prices reflect investors' perceptions of the future prospects and financial health of Xeris Pharmaceuticals, and Xeris Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Xeris Stock performance.
| Return On Equity | -6.17 | ||||
| Return On Asset | -0.0533 | ||||
| Profit Margin | (0.27) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 941.25 M | ||||
| Shares Outstanding | 153.94 M | ||||
| Price To Book | 3.34 X | ||||
| Price To Sales | 3.65 X | ||||
| Revenue | 203.07 M | ||||
| Gross Profit | 166.24 M | ||||
| EBITDA | (13.99 M) | ||||
| Net Income | (54.84 M) | ||||
| Cash And Equivalents | 111.55 M | ||||
| Cash Per Share | 0.82 X | ||||
| Total Debt | 271.45 M | ||||
| Debt To Equity | 1.87 % | ||||
| Current Ratio | 2.50 X | ||||
| Book Value Per Share | (0.20) X | ||||
| Cash Flow From Operations | (36.98 M) | ||||
| Earnings Per Share | (0.37) X | ||||
| Market Capitalization | 741.99 M | ||||
| Total Asset | 323.06 M | ||||
| Retained Earnings | (671.86 M) | ||||
| Working Capital | 67.22 M | ||||
About Xeris Pharmaceuticals Performance
Assessing Xeris Pharmaceuticals' fundamental ratios provides investors with valuable insights into Xeris Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Xeris Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 477.41 | 296.41 | |
| Return On Tangible Assets | (0.27) | (0.29) | |
| Return On Capital Employed | (0.15) | (0.16) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | 1.85 | 1.94 |
Things to note about Xeris Pharmaceuticals performance evaluation
Checking the ongoing alerts about Xeris Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Xeris Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Xeris Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Xeris Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 203.07 M. Net Loss for the year was (54.84 M) with profit before overhead, payroll, taxes, and interest of 166.24 M. | |
| Xeris Pharmaceuticals currently holds about 111.55 M in cash with (36.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.82. | |
| Xeris Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Xeris Pharmaceuticals stock hits 52-week high at 4.69 - Investing.com |
- Analyzing Xeris Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Xeris Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Xeris Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Xeris Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Xeris Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Xeris Pharmaceuticals' stock. These opinions can provide insight into Xeris Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.